Osteoarthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026

Osteoarthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026

Nov 2018 Transparency Market Research Pharmaceutical185 Pages Price :
$ 5795

Global Osteoarthritis Drugs Market: Overview

This report analyzes the current and future scenario of the global osteoarthritis drugs market for the period 2018 to 2026. Rise in geriatric population, prevalence of obesity, high unmet medical needs, and rich pipeline are likely to be major drivers of the global osteoarthritis drugs market during the forecast period.

The global osteoarthritis drugs market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, route of administration, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the global osteoarthritis drugs market.

Global Osteoarthritis Drugs Market: Key Segments

Based on drug class, the global osteoarthritis drugs market has been segmented into corticosteroids, NSAIDs & others, and viscosupplementation agents. The segments have been analyzed based on available drugs used during the treatment of osteoarthritis, and cost-effectiveness. In terms of route of administration, the global osteoarthritis drugs market has been classified into oral, parenteral, and topical. Based on distribution channel, the global osteoarthritis drugs market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Global Osteoarthritis Drugs Market: Regional Outlook

In terms of region, the global osteoarthritis drugs market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players operating in the global osteoarthritis drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics Inc., Ferring B.V., Bioventus Inc, Chugai Pharmaceutical Co. Limited, Alkem Laboratories, Flexion Therapeutics Inc., and Zimmer Biomet Holdings Inc.

The global osteoarthritis drugs market has been segmented as below:

Global Osteoarthritis Drugs Market, by Drug Class

  • Corticosteroids
  • NSAIDs & Others
  • Viscosupplementation Agents

Global Osteoarthritis Drugs Market, by Route Of Administration

  • Oral
  • Parenteral
  • Topical

Global Osteoarthritis Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Osteoarthritis Drugs Market, by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • South Africa
  • GCC Countries
  • Rest of Middle East & Africa

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Osteoarthritis Drugs Market 

4. Market Overview
4.1. Overview
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2016–2026
4.4.1. Global Osteoarthritis Drugs Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Disease Prevalence & Incidence Rate globally with key countries
5.2.Regulatory Scenario by Region/globally
5.3.Pipeline Analysis

6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Corticosteroids
6.3.2. NSAIDs & others
6.3.3. Viscosupplementation Agents 
6.4. Global Osteoarthritis Drugs Market Attractiveness by Drug Class 

7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration 
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
7.3.1. Oral  
7.3.2. Parenteral 
7.3.3. Topical 
7.4. Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration 

8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel 
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospital pharmacies 
8.3.2. Retail pharmacies 
8.3.3. Online pharmacies 
8.4. Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel 

9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Osteoarthritis Drugs Market Value Forecast, by Region
9.2.1. North America 
9.2.2. Europe 
9.2.3. Asia Pacific 
9.2.4. Latin America 
9.2.5. Middle East & Africa 
9.3. Global Osteoarthritis Drugs Market Attractiveness, by Region

10. North America Osteoarthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. North America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
10.2.1.Corticosteroids
10.2.2. NSAIDs & Others
10.2.3.Viscosupplementation agents 
10.3. North America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
10.3.1. Oral  
10.3.2. Parenteral 
10.3.3. Topical 
10.4. North America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital pharmacies 
10.4.2. Retail pharmacies 
10.4.3. Online pharmacies 
10.5. North America Osteoarthritis Drugs Market Value Forecast, by Country, 2016–2026
10.5.1. US
10.5.2. Canada 
10.6. North America Osteoarthritis Drugs Market Attractiveness Analysis 
10.6.1. By Drug Class 
10.6.2. By Route of Administration 
10.6.3. By Distribution Channel 
10.6.4. By Country

11. Europe Osteoarthritis Drugs Market Analysis and Forecast
11.1.Introduction
11.2. Europe Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Corticosteroids
11.2.2. NSAIDs & Others
11.2.3. Viscosupplementation agents 
11.3. Europe Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
11.3.1. Oral  
11.3.2. Parenteral 
11.3.3. Topical 
11.4. Europe Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital pharmacies 
11.4.2. Retail pharmacies 
11.4.3. Online pharmacies 
11.5. Europe Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. France
11.5.3. U.K.
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Osteoarthritis Drugs Market Attractiveness Analysis 
11.6.1. By Drug Class 
11.6.2. By Route of Administration 
11.6.3. By Distribution Channel 
11.6.4. By Country/Sub-region

12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
12.1.Introduction
12.2. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Corticosteroids
12.2.2. NSAIDs & Others
12.2.3. Viscosupplementation agents 
12.3. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
12.3.1. Oral  
12.3.2. Parenteral 
12.3.3. Topical 
12.4. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital pharmacies 
12.4.2. Retail pharmacies 
12.4.3. Online pharmacies 
12.5. Asia Pacific Osteoarthritis Drugs Market Value Forecast by Country/Sub-region, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis 
12.6.1. By Drug Class 
12.6.2. By Route of Administration 
12.6.3. By Distribution Channel 
12.6.4. By Country/Sub-region

13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
13.1.Introduction
13.2. Latin America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Corticosteroids
13.2.2. NSAIDs & Others
13.2.3. Viscosupplementation agents 
13.3. Latin America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
13.3.1. Oral  
13.3.2. Parenteral 
13.3.3. Topical 
13.4. Latin America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital pharmacies 
13.4.2. Retail pharmacies 
13.4.3. Online pharmacies 
13.5. Latin America Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Osteoarthritis Drugs Market Attractiveness Analysis 
13.6.1. By Drug Class 
13.6.2. By Route of Administration 
13.6.3. By Distribution Channel 
13.6.4. By Country/Sub-region

14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
14.1.Introduction
14.2. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
14.2.1. Corticosteroids
14.2.2. NSAIDs & Others
14.2.3. Viscosupplementation agents 
14.3. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
14.3.1. Oral  
14.3.2. Parenteral 
14.3.3. Topical 
14.4. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital pharmacies 
14.4.2. Retail pharmacies 
14.4.3. Online pharmacies 
14.5. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Country/Sub-regions, 2016–2026
14.5.1. GCC Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis 
14.6.1. By Drug Class 
14.6.2. By Route of Administration 
14.6.3. By Distribution Channel 
14.6.4. By Country

15. Competition Landscape
15.1. Global Osteoarthritis Drugs Market Player – Competition Matrix (by Tier and Size of companies)
15.2. Global Osteoarthritis Drugs Market Share Analysis, by Company (2016)
15.3. Company Profiles
15.3.1. Horizon Pharma plc. 
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi 
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Anika Therapeutics, Inc.  
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ferring B.V.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bioventus, Inc. 
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Chugai Pharmaceutical Industries Limited  
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Alkem Laboratories
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Flexion Therapeutics, Inc.  
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Zimmer Biomet Holdings, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview

List of Table

Table 01: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 06: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 07: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 09: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 10: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 11: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 12: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 13: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 14: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 15: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 18: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 19: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 20: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 24: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Chart

Figure 01: Global Osteoarthritis Drugs Market Snapshot
Figure 02: Global Fluid Management Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, 2016?2026
Figure 04: Global Osteoarthritis Drugs Market Value Share, by Drug Class (2017)
Figure 05: Global Osteoarthritis Drugs Market Value Share, by Route of Administration (2017)
Figure 06: Global Osteoarthritis Drugs Market Value Share, by Distribution Channel (2017)
Figure 07: Global Osteoarthritis Drugs Market Value Share, by Region (2017)
Figure 08: Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 09: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids
Figure 10: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Others
Figure 11: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Viscosupplementation Agents
Figure 12: Global Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 13: Global Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 14: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2016–2026
Figure 15: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2016–2026
Figure 16: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2016–2026
Figure 17: Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 18: Global Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 19: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 20: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 21: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016–2026
Figure 22: Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 23: Global Osteoarthritis Drugs Market Value Share Analysis, by Region 2017 and 2026
Figure 24: Global Osteoarthritis Drugs Market Attractiveness, by Region, 2018–2026
Figure 25: North America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: North America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 27: North America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 28: North America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 29: North America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 30: North America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 31: North America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 32: North America Osteoarthritis Drugs Market Value Share (%), by Country, 2017 and 2026
Figure 33: North America Osteoarthritis Drugs Market Attractiveness, by Country, 2018–2026
Figure 34: Europe Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 35: Europe Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 36: Europe Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 37: Europe Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 38: Europe Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 39: Europe Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 40: Europe Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 41: Europe Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 42: Europe Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 43: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 44: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 45: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 46: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 47: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 48: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 49: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 50: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 51: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 52: Latin America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 53: Latin America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 54: Latin America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 55: Latin America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 56: Latin America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 57: Latin America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 58: Latin America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 59: Latin America Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 60: Latin America Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 61: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 62: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 63: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 64: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 65: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 66: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 67: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 68: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 69: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 70: Global Osteoarthritis Drugs Market Share Analysis, by Company (2017)
Figure 71: Horizon Pharma plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 72: Horizon Pharma plc. Breakdown of Net Sales, by Region, 2017
Figure 73: Horizon Pharma plc. Breakdown of Net Sales, by Drug, 2017
Figure 74: Horizon Pharma plc. Research & Development Cost (US$ Mn), 2015–2017
Figure 75: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 76: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
Figure 77: Sanofi Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 78: Sanofi Breakdown of Net Sales, by Region, 2017
Figure 79: Sanofi Breakdown of Net Sales, by Business Segment, 2017
Figure 80: Sanofi Research & Development Cost, 2015–2017 (US$ Mn)
Figure 81: Anika Therapeutics, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 82: Anika Therapeutics, Inc. Breakdown of Net Sales, by Region, 2017
Figure 83: Anika Therapeutics, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 84: Anika Therapeutics, Inc. Research & Development Cost, 2015–2017 (US$ Mn)
Figure 85: Chugai Pharmaceutical Co., Limited. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 86: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Region, 2017
Figure 87: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Business Segment, 2017
Figure 88: Chugai Pharmaceutical Co., Limited. Research & Development Cost (US$ Mn), 2015–2017
Figure 89: Alkem Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 90: Alkem Laboratories Breakdown of Net Sales, by Region, 2017
Figure 91: Alkem Laboratories Breakdown of Net Sales, by Business Segment, 2017
Figure 92:  Alkem Laboratories Research & Development Cost (US$ Mn), 2015–2017
Figure 93: Zimmer Biomet Holdings, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 94:  Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Region, 2017
Figure 95:  Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 96:  Zimmer Biomet Holdings, Inc. Research & Development Cost (US$ Mn), 2015–2017

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 5795
$ 8795

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top